EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Tanning & Melanocortin Peptides
Melanotan peptides act on the melanocortin system—the peptide signaling pathway that controls skin pigmentation, appetite, inflammation, and sexual function. Three compounds here are FDA-approved for distinct indications.
The melanocortin receptors (MC1R through MC5R) are among the most pharmacologically versatile peptide targets in the body. Different receptor subtypes mediate vastly different biological effects.
Cluster at a Glance
|
6 Compounds Covered |
3 Approved Drug |
2 Clinical Trials |
1 Preclinical Only |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
Preclinical Only Animal models and cell culture only |
BLUF: Bottom Line Up Front
Three FDA-approved drugs: ACTH (Acthar Gel) for infantile spasms and inflammatory conditions, Afamelanotide (Scenesse) for erythropoietic protoporphyria, and Setmelanotide (Imcivree) for rare genetic obesity. Melanotan I reached clinical trials for photoprotection but was not pursued commercially. PL-8177 is a promising MC1R-selective agonist in Phase II for ulcerative colitis—potentially decoupling anti-inflammatory effects from pigmentation. Alpha-MSH is the endogenous parent peptide that inspired all the others. This cluster is defined by receptor selectivity: the difference between a tanning agent, an obesity drug, and an anti-inflammatory comes down to which melanocortin receptor a compound prefers.
In This Article
Compounds in This Cluster
All 6 compounds in the Tanning & Melanocortin Peptides cluster, organized by mechanism and editorial function. Each grouping reflects how these compounds relate to each other scientifically—not just alphabetically.
Group 1 of 3
The Approved Melanocortin Drugs
FDA-approved compounds targeting different melanocortin receptor subtypes for distinct clinical indications.
Group 2 of 3
The Clinical Pipeline
Melanocortin compounds in clinical trials with potential to decouple specific receptor-mediated effects.
|
|
Group 3 of 3
The Endogenous Peptide
The natural parent molecule that inspired all synthetic melanocortin compounds.
|
How These Compounds Relate
Every compound in this cluster derives from or targets the melanocortin receptor family—five G-protein coupled receptors (MC1R through MC5R) that evolved from a single ancestral gene. Alpha-MSH, the endogenous parent peptide, activates all five subtypes, which is why it simultaneously affects pigmentation (MC1R), adrenal function (MC2R), appetite (MC3R/MC4R), and immune regulation (MC1R/MC3R). ACTH is the broadest synthetic version: it hits all five receptors, producing a wide range of effects that make it both therapeutically useful and difficult to target precisely.
The pharmaceutical development story in this cluster is one of increasing selectivity. Afamelanotide preferentially targets MC1R for pigmentation without strong appetite or adrenal effects. Setmelanotide is MC4R-selective for satiety signaling without significant pigmentation. PL-8177 may be the most elegant—an MC1R-selective agonist being developed for anti-inflammatory effects in ulcerative colitis, attempting to harness the immune modulation of the melanocortin system while minimizing skin darkening.
Melanotan I bridges the early (non-selective) and modern (selective) eras of melanocortin pharmacology. It demonstrated clinical proof-of-concept for photoprotection, and its analogue Afamelanotide ultimately received FDA approval for the narrow indication of EPP—validating the MC1R mechanism but illustrating how difficult it is to commercialize a tanning peptide in a regulatory environment that rightly demands disease-specific indications.
| Shared Mechanism | Compounds |
|
Pan-Melanocortin Activation Activates all five melanocortin receptor subtypes, producing broad effects on pigmentation, adrenal function, appetite, and immunity. |
ACTH, Alpha-MSH |
|
MC1R Pigmentation / Photoprotection Selectively activates MC1R on melanocytes to stimulate eumelanin production and increase photoprotective skin pigmentation. |
Afamelanotide, Melanotan I |
|
MC4R Satiety Signaling Selectively activates MC4R in the hypothalamus to restore the POMC-mediated satiety pathway disrupted in genetic obesity. |
Setmelanotide |
|
MC1R Anti-Inflammatory Targets MC1R-mediated anti-inflammatory signaling to suppress mucosal inflammation without systemic pigmentation effects. |
PL-8177 |
Plain English
All six compounds here work through the same family of receptors, but which receptor they prefer determines what they do. Hit MC1R and you get darker skin (Afamelanotide). Hit MC4R and you feel full (Setmelanotide). Hit MC1R in the gut and you suppress inflammation (PL-8177). Hit everything at once and you get the complex effects of ACTH. The story of this cluster is pharmaceutical companies learning to be more precise—starting with the broad, blunt instrument of ACTH and gradually developing compounds that activate only the receptor subtype responsible for the specific effect they want.
Stay Current
New research, new articles, no noise
Peptidings publishes long-form peptide research articles grounded in primary literature. Subscribe to get new compound articles, cluster updates, and evidence reviews delivered to your inbox.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.